Aprotinin use during cardiac surgery: A new or continuing controversy?

Anesthesia and Analgesia

Volumn 103, Issue 5, 2006, Pages 1067-1070

  Hogue, Charles W ^a   London, Martin J ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIARRHYTHMIC AGENT; ANTIFIBRINOLYTIC AGENT; APROTININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYPERTENSIVE FACTOR; INOTROPIC AGENT; PLACEBO; TRANEXAMIC ACID; VASOACTIVE AGENT;

BLOOD TRANSFUSION; CARDIOTOXICITY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DEATH; DIALYSIS; DOSE RESPONSE; EDITORIAL; HEART INFARCTION; HEART SURGERY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; THROMBOSIS;

APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DRUG LABELING; HUMANS;

EID: 33750375037     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000247881.20257.6d     Document Type: Editorial

References (25)

1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion med-blood transfusion. N Engl J Med 1999;340:438-47.
2. Moulton MJ, Creswell LL, Mackey ME, et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995;59:664-7.
3. Possible transfusion-associated acquired immune deficiency syndrome (AIDS) - California. MMWR Morb Mortal Wkly Rep 1982;31:652-4.
4. Groezinger KH, Hollis AU, Artz CP. Experimental studies on prevention of fatal pancreatitis. J Am Med Assoc 1964;187:652-4.
5. Katz W, Mammen EF, Thal AP. Inhibition of fibrinolysis during extracorporeal circulation. Surg Forum 1965;16:63, 64.
6. Tice DA, Worth MH Jr, Clauss RH, Reed GH. The inhibition of Trayslol of fibrinolytic activity associated with cardiovascular operations. Surg Gynecol Obstet 1964;119:71-4.
7. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
8. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
9. www.fda.gov/cder/.
10. Mangano DT, Tudor IC, Dietzel C; for the Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
11. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in hightransfusion-risk cardiac surgery. Transfusion 2006;46:327-38.
12. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005;80:1388-93.
13. Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 2006;103:1074-81.
14. Royston D, Levy J, Fitch J, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 2006;103:1082-8.
15. Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996;82:13-21.
16. Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg 1996;623:1575-7.
17. Seghaye M-C, Duchateau J, Grabitz RG, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg 1996;61:1205-11.
18. Henry DA, Moxey AJ, Carless PA, O'Connell D, et al. Antifibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 1999(4):CD001886.
19. Davila-Roman VG, Kouchoukos, NT, Schechtman KB, Barzilai B. Atherosclerosis of the ascending aorta is a predictor of renal dysfunction after cardiac operations. J Thorac Cardiovasc Surg 1999;117:111-16.
20. Hogue CW Jr, Murphy SF, Schechtman KB, Davila-Roman VG. Risk factors for early or delayed stroke after cardiac surgery. Circulation 1999;100:642-7.
21. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
22. Sundt TM III, Kouchoukos NT, Saffitz JE, et al. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418-24.
23. http://www.controlled-trials.com/isrctn/trial/%7C/0/15166455.html.
24. http://www.fda.gov/cder/drug/advisory/aprotinin.htm.
25. www.fda.gov/medwatch/report.htm.